The current reference price of Karelizumab is 2,928 yuan a bottle, but due to the different reimbursement amount of medical insurance around the world, patients need to pay the cost also varies. The specification of Karelizumab is 200mg/bottle, this product has entered the medical insurance. Its price is 2928 yuan a bottle, due to the different reimbursement amount of medical insurance in various regions, patients need to pay different costs, the specific price is recommended to consult the local regular hospitals. Karelizumab clinically is mainly used in the treatment of classical Hodgkin’s lymphoma that has undergone second-line systemic chemotherapy. Its adverse reactions include anemia, reactive capillary hyperplasia, malaise, fever, proteinuria, hypothyroidism, etc. It is contraindicated for those who are allergic to this product. Please use the drug under the guidance of a physician, and consult a physician promptly if significant discomfort occurs after administration.